These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Madsen S Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650 [No Abstract] [Full Text] [Related]
5. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure. Madsen S; Olgaard K Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464 [TBL] [Abstract][Full Text] [Related]
6. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease. Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662 [No Abstract] [Full Text] [Related]
7. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure. Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943 [No Abstract] [Full Text] [Related]
8. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033 [No Abstract] [Full Text] [Related]
9. 1-alpha-hydroxycholecalciferol for renal osteodystrophy. Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269 [TBL] [Abstract][Full Text] [Related]
11. Curative effects of 1alpha-hydroxycholecalciferol on calcium metabolism and bone disease in patients with chronic renal failure. Hirooka M; Wako H; Kaneko C; Ishikawa M; Sasaki S J Nutr Sci Vitaminol (Tokyo); 1975; 21(4):277-85. PubMed ID: 1214180 [TBL] [Abstract][Full Text] [Related]
12. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy. Junor BJ; Catto GR Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411 [TBL] [Abstract][Full Text] [Related]
13. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534 [TBL] [Abstract][Full Text] [Related]
14. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol. Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833 [TBL] [Abstract][Full Text] [Related]
16. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358 [TBL] [Abstract][Full Text] [Related]
17. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Rix M; Eskildsen P; Olgaard K Nephrol Dial Transplant; 2004 Apr; 19(4):870-6. PubMed ID: 15031343 [TBL] [Abstract][Full Text] [Related]